Who is running the CDC? Why is that person not there? You've got Marty (FDA) and Jay (NIH) with RFK Jr. But nobody from CDC. Is it because, as I've reported, there is no Acting CDC Director and that Secretary Kennedy is the only person making vaccine policy?

Story on the SiteOne deal from Jacob Bell here: biopharmadive.com/news/lilly-sit… and more on NaV1.8 inhibitors from Jacob in his deep dive on $VRTX's Journavx here: biopharmadive.com/news/pain-drug…

HHS Secretary RFK Jr. heralded the Make America Healthy Again report as a “milestone.” NOTUS found some problems with its bibliography. “The paper cited is not a real paper that I or my colleagues were involved with,” one cited researcher told us. notus.org/health-science…

Looking at the citations is the definition of engaging with the substance.

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say My latest — endpoints.news/sources-fda-ch…

Breaking: The U.S. FDA's CDER announces Mike Davis, former team leader in the FDA Division of Psychiatry and current Usona Institute CMO, will become CDER deputy director.

Oz hints at impending CMS rule to force drug price transparency healthcaredive.com/news/drug-pric… via Healthcare Dive

Some of the reasons for $VERV board recommending the $LLY transaction

Meissner praises the antibodies used to prevent RSV and calls data a “spectacular accomplishment.” “People should understand this is a truly spectacular accomplishment and will have enormous impact on on public health.”

CDC ACIP vote for today is postponed:

As ACIP discusses thimerosal in vaccines, Cody Meissner, a pediatrician and committee member, offers a quote of the day contender: "Of all the issues that ACIP needs to focus on, this is not a big issue."

We've updated BioPharma Dive's 2025 trials to watch list with 10 readouts expected in the second half of the year. A few of the 10 we flagged for H1 are still pending, too. Check them all out here: biopharmadive.com/news/biotech-p…

Sodium channel blockers for pain: New opportunities after Vertex’s ‘watershed’ moment biopharmadive.com/news/sodium-ch… A deep look at the pipeline of NaV1.8 and NaV1.7 drugs behind Journavx, via Jacob Bell.

New from me: RFK Jr. says he has brought in a team of people to work on expanding the vaccine injury compensation program — which would require help from Congress. HHS did not tell me who is on the team: statnews.com/2025/07/01/rfk…

NCI to license in vivo CD19 Car-T patents (specifically for autoimmune) to Capstan. Necessary to supplement IP behind CPTX2309? I wonder if US govt will get a cut of the $2bn from $ABBV, LOL! public-inspection.federalregister.gov/2025-12409.pdf

AstraZeneca is discussing a partnership deal with Summit Therapeutics in which it could pay as much as $15 billion over time to license a lung-cancer drug bloomberg.com/news/articles/…

Esobiotec's in vivo CAR-T data out in Lancet, n=4, multiple myeloma. These are the data that drove the $AZN acquisition, showing that the in vivo CAR-T results were equal to the ex vivo CAR-T results from Pregene w the same BCMA-CAR thelancet.com/journals/lance…

Targeted protein degraders take many forms: PROTACs, molecular glues, LYTACs, EPITACs and so on. Gwendolyn Wu dug into the fast-growing field and where it may be going next in BioPharma Dive's latest 'State of Play': biopharmadive.com/news/protein-d…